The global HIV antivirals market is set to reach a valuation of USD 30.6 Billion in 2022, and register a CAGR of 4.4% during the forecast period (2022 to 2032). According to a recent study, fixed-dose combinations (FDCs) are leading the HIV antivirals market with a share of over 83% in 2021.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| HIV Antivirals Market Value 2021 | USD 29.4 Billion |
| Market Value 2022 | USD 30.6 Billion |
| Market Value 2032 | USD 47.0 Billion |
| CAGR 2022 to 2032 | 4.4% |
| Market Share of Top 5 Countries | 64.8% |
The demand for HIV antivirals is projected to surge with increasing access to effective HIV diagnosis, treatment, prevention, and care. It makes HIV infection a manageable chronic health condition such as cancer and tuberculosis, which enables people living with HIV to lead healthy and long lives.
The HIV antivirals market is poised to expand on the back of rising awareness about HIV causes, symptoms, and available treatment options. There are various awareness programs organized by the USA Department of Health & Human Services for creating awareness regarding HIV and its testing.
For instance, the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) observe the day 18th May as HIV Vaccine Awareness Day. This is to show gratitude towards the community members, volunteers, healthcare professionals, and scientists working together to find a safe and effective preventive HIV vaccine.
Explore FMI!
Book a free demo
Overall sales of HIV antivirals expanded at a CAGR of 4.0% from 2017 to 2021 owing to the rise in various government and NGO plans to offer greater accessibility to disease diagnosis and treatment for infected persons. As per Future Market Insights (FMI), the demand for HIV antivirals was approximately 66.5%, totalling USD 44.2 Billion of the global antiviral drugs market in 2021.
For instance, the International AIDS Society (IAS) is the world’s largest association of HIV professionals from more than 170 countries. It plays a vital role in improving the lives of people with and most vulnerable to acquiring HIV by promoting the implementation of evidence-informed and human rights-based strategies.
Rising initiatives by government across the globe and NGOs is expected to boost the HIV antiviral market. Hence, key players operating in the market are capitalizing on this existing trend by launching new products.
For instance, in January 2021, ViiV Healthcare gained marketing authorization from European Commission for Tivicay (dolutegravir) for the treatment of human immunodeficiency virus (HIV-1) infection in pediatric patients.
In addition, increasing awareness about the available treatments to control HIV growth is also enhancing the demand for the HIV antivirals market.
Key manufacturers in HIV antivirals market are actively participating in clinical trials for the development of HIV antivirals. For instance, ViiV Healthcare is sponsoring “the study to evaluate the antiviral effect, safety and tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 infected adults”, which is currently in phase 2.
Similarly, the National Institute of Allergy and Infectious Diseases (NIAID) is also sponsoring a project named “Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents”, which is currently in phase 2. On the back of these developments, the demand in the HIV antivirals market is expected to propel over the assessment period.
The market is being impacted by limited access to HIV treatment and a lack of awareness in emerging nations. One-fifth of the urban population is HIV-positive and unaware of it. Increased HIV testing among the general population could be one way for regional and national planning actions to address this issue.
Rigorous government guidelines for the approval and commercialization of HIV drugs is also creating a hurdle for the growth of the market by limiting the number of drugs launched every year for HIV. Thus, it is harming the overall market growth.
Additionally, the lack of advanced infrastructure and limited facilities for screening and testing may limit the population with HIV infection to opt for proper treatment.
Furthermore, a large number of under-diagnosed populations is increasing due to a lack of adequate data to guide country-specific testing approaches, lack of guidelines on testing for resource-limited settings, and stigmatization of populations with or at high risk of infection.
Availability of Funded Drug Assistance Programs in the USA to Propel Growth in HIV Antivirals Market
The USA dominated the North America HIV antivirals market with a total market share of around 96.8% in 2021. Demand for HIV antivirals is expected to surge due to the presence of various federally funded assistance programs in the country.
For instance, the AIDS Drug Assistance Program (ADAP) helps people with less income pay for HIV and AIDS medications. In many states, it covers extra costs such as prescription drugs and lab tests that are not for treating HIV/AIDS.
Thus, USA market will have a great opportunity in the region for growth, due to better assistance programs in the approaching years.
Favorable Government and NGO Policies to Boost the UK HIV Antivirals Market
As per FMI, the UK is set to exhibit a CAGR of nearly 4.3% in the Europe HIV antivirals market during the forecast period. Government in the UK provides all HIV treatment free for the residents in the country, regardless of their immigration status. These kinds of facilities aid the middle and low-income population to take the best treatment for HIV.
Moreover, the approval for the use of injectable treatment using a combination of cabotegravir with rilpivirine instead of oral antiretroviral is a better treatment option for HIV patients. This is due to the dosing frequency of injectable is much lower than the oral dosage.
Rising Prevalence of HIV to Improve the Demand for HIV Vaccine Boosting China HIV Antivirals Market
China held more than 75% share in the East Asia HIV antivirals market in 2021 and is projected to increase at a CAGR of 4.4% during the forecast period. Demand in the market is projected to surge on the back of rising prevalence of HIV in China.
For instance, according to studies published in NCBI, approximately 1.1 million people were living with HIV in 2020 in China. The demand for HIV antivirals is increasing with the growing rate of infection to treat or manage the disease.
Demand for HIV Drugs to Surge in India Amid Growing Cases of HIV and Rising Infant Mortality Rate
India held around 45.3% share in South Asia HIV antivirals market in 2021 and is projected to register a CAGR of 4.8% during the forecast period. Growth is primarily due to the high infant mortality rate and presence of HIV cases in the country.
Further, presence of awareness programs in the country, such as the National Aids Control Programme, is a key factor accelerating the demand in the market. It is a centrally sponsored scheme run by the Ministry of Health and Family Welfare of the Government of India with the goal of halving new HIV/AIDS infections and providing comprehensive care, support, and treatment to all HIV/AIDS patients.
Fixed Dose Combinations (FDCs) to Account for Over 4/5th of HIV Antivirals Sales
Fixed dose combinations (FDCs) held a market share of around 83.2% in 2021 and is estimated to witness growth at a CAGR of 4.5% during the forecast period.
High demand for FDCs drugs is due to the simplicity of the regimen, drug-drug interactions, and infrequent adverse effects in combination with a low pill burden. It also prevents the virus to reproduce by restricting an enzyme HIV needs to make copies of itself.
Thus, FDCs drugs help to improve adherence to an HIV treatment regimen which drives the demand for FDCs in forthcoming years.
Sales of HIV Antivirals in Hospital Pharmacies to Surge at a Robust Pace
The hospital pharmacies segment held a market share of 53.4% in 2021 and is expected to hold a share of over 54.0% in 2032.
Increasing number of people seeking treatment in hospitals are purchasing the drugs through hospital pharmacies. This is due to factors such as easy availability and subsidized prices. Thus, hospital pharmacies help in increasing the sale of HIV antiviral drugs and will drive the HIV antivirals market.
Key players in the HIV antivirals market are concentrating on collaborations and gaining FDA approvals, as the key strategies for expanding their business in the market.
These factors will support the market players, such as Theratechnologies and AbbVie, to improve their product portfolio together with market penetration, thus, increasing their revenue share in the global market.
For instance:
| Attributes | Details |
|---|---|
| Market Value 2022 | USD 30.6 Billion |
| Market Value 2032 | USD 47.0 Billion |
| CAGR 2022-2032 | 4.4% |
| Forecast Period | 2017 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, China, Japan, Germany, Canada, UK, India, South Korea, Russia, Australia, BENELUX, Spain, Indonesia, France, Italy, Brazil, Thailand, Malaysia, Vietnam, Philippines, Mexico, GCC Countries, Argentina, South Africa, North Africa, Turkey, and New Zealand |
| Key Market Segments Covered | Product, Sales Channel, and Region |
| Key Companies Profiled | ViiV Healthcare; Gilead Sciences, Inc.; GlaxoSmithKline plc; Merck & Co., Inc.; Johnson & Johnson; Genetech, Inc.; Teva Pharmaceutical Industries Ltd.; AbbVie; Cipla; Pfizer Inc.; Mylan N.V.; Bristol-Myers Squibb Company; Boehringer Ingelheim International ; GmbH; Macleods Pharmaceuticals Ltd; Emcure Pharmaceuticals Limited; Aspen Pharmacare Limited; Lupin Ltd.; Sun Pharmaceutical Industries Ltd.; Theratechnologies Inc.; Strides Arcolab Limited; Hetero labs limited; Laurus Laboratories Ltd |
The global HIV antivirals market is worth USD 29.4 Billon in 2021 and is set to expand 1.5X over the next ten years.
The HIV antivirals market is expected to reach USD 47.0 Billion by the end of 2032, with sales revenue expected to register a 4.4% CAGR over the forecast period (2022 to 2032).
Increasing research and development activities to develop long-acting antiviral therapies, the rising number of clinical trials, and the increasing number of product launches, are some of the key trends in this market.
The U.S., Germany, India, China, and the U.K. are expected to drive demand for the HIV antivirals industry.
North America is one of the key markets for HIV antivirals and the U.S. is accounting for around 96.8% of the North American market in the year 2021.
The demand for HIV antivirals in Europe is expected to register a growth of 4.1% over the next ten years.
HIV Antivirals Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
